Abstract:Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.

Inborn errors of IL-6 family cytokine responses

Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome

The Human GP130 Cytokine Receptor and Its Expression—an Atlas and Functional Taxonomy of Genetic Variants

Abstract 5511: Lineage-specific and Shared Cytokine-Sensing Genes Respond Distinctly to the Master Regulator STAT5

Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis.

A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

Structural insights into IL-11-mediated signalling and human IL6ST variant-associated immunodeficiency

Infections in Inborn Errors of STATs

IL-6 signal transduction and its physiological roles: the signal orchestration model

JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity

JAK/STAT defects and immune dysregulation, and guiding therapeutic choices

Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms.

Severe Allergic Dysregulation Due to A Gain of Function Mutation in the Transcription Factor STAT6

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

Human lymphoid development in the absence of common γ-chain receptor signaling

Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond

IL-6 in inflammation, immunity, and disease.

Targeting IL-6 trans-signalling: past, present and future prospects

Dysregulation of epigenetic modifications in inborn errors of immunity

Human Germline Heterozygous Gain-of-Function STAT6 Variants Cause Severe Allergic Disease